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Introduction: Vitamin D deficiency and vitamin D receptor (VDR) gene polymorphism, FokI, is reported to increase
the risk of many cancers. Role of vitamin D and its receptor polymorphisms in ovarian cancer has not been clearly
defined.
Objective: To study the levels of serum vitamin D and occurrence of vitamin D receptor gene polymorphism (FokI)
in cases of ovarian cancer.
Material and methods: FokI genotyping was done by PCR-RFLP technique and vitamin D levels were estimated by
chemiluminescence immunoassay.
Results: Serum vitamin D levels were significantly (p < 0.03) lower in ovarian cancer cases as compared to controls.
The homozygous (TT) and heterozygous (CT) genotype predispose to the development of ovarian cancer in Indian
population (OR: 2.37, 95% CI: 1.04-5.44) as compared to the homozygous (CC) genotype. Vitamin D deficiency and
VDR gene polymorphism (FokI) act non-synergistically (p value < 0.4).
Conclusion: Low blood levels of vitamin D and VDR receptor polymorphism (FokI) might be a risk factor for the
development of ovarian cancer. Other novel ligands of vitamin D receptor might be responsible for the non-
synergistic effect.Introduction
Ovarian cancer is the 6th most common cancer in
women with estimated lifetime risk of 1 in 70 women
[1]. Epithelial ovarian cancer is the most common histo-
logical type of ovarian cancer. More than seventy per-
cent of these patients present in the advanced stage of
this disease, and have a cure rate of less than forty per-
cent [2]. The high mortality in these cases is due to lack
of highly sensitive and specific screening methods.
Vitamin D is a fat soluble secosteroid which is in-
volved in a wide variety of biological processes like bone
metabolism, modulation of immune response, cell prolif-
eration and cell differentiation. There exists an inverse
relationship between vitamin D levels in blood and inci-
dence of many cancers [3,4]. The studies conducted by
Arslan et al. and Tworoger et al. couldn’t establish any
direct relationship between vitamin D deficiency and risk
of ovarian cancer [5,6]. But Tworoger et al. reported that* Correspondence: sudhesna.moh@gmail.com
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distribution, and reproduction in any mediumvitamin D deficiency is associated with significant risk of
ovarian cancer in overweight and obese women [6]. Ac-
tivity of vitamin D is mediated by vitamin D receptor
(VDR). VDR gene polymorphism, FokI, (rs10735810/
rs2228570) is reported to be in linkage disequilibrium
with other VDR polymorphisms. A change in the se-
quence from C to T in the start codon translation site
leads to generation of a polymorphic variant (TT) which
is three amino acids longer and has decreased transacti-
vation capacity as compared to the short CC allele [7].
Several population based studies indicated that VDR
gene polymorphisms are associated with human cancers
[8,9]. A few studies tried to establish a relationship be-
tween vitamin D receptor gene polymorphism (FokI)
and ovarian cancer. The odds ratio in these studies were
observed to vary from 1.09 to 2.5 indicating that CT and
TT genotypes of VDR gene polymorphism (FokI) are at
increased risk of ovarian cancer[10-13]. However there
is hardly any data in this regard in the Indian popula-
tion. Hence the present study was designed (a) to evalu-
ate the levels of serum vitamin D in epithelial ovarian
cancer patients, (b) to evaluate the association oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Fok I Restriction digested PCR product of VDR gene. L4-100 bp molecular weight marker; L3-Homozygous TT genotype, L2-
Homogygous CC genotype, L1-heterozygous CT genotype.







Age in yr 47.9 ± 13.35 47.2 ± 12.4
Menopausal status
Pre-menopausal 19 (38%) 20 (40%)
Post-menopausal 31 (62%) 30 (60%)
Subjects with positive family
history of breast or ovarian cancer
3 1 0.50
Parity:
Nulliparous 4 1 0.18
1 4 4 0.13
2-3 29 36 0.14
≥ 4 13 9 0.23
History of use of oral contraceptives 4 6 0.37
Tubal ligation 11 5 0.08
* by chi square test.
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with the risk of epithelial ovarian cancer and (c) to ex-
plore if the relationship between vitamin D levels and
vitamin D receptor polymorphism FokI is additive in
their action.
Material and methods
A case control study was designed to recruit fifty subjects
in each group and conducted in the department of Bio-
chemistry and department of Obstetrics and Gynecology,
Maulana Azad Medical College, New Delhi. Written in-
formed consent was taken from the cases and controls.
Blood sample (5 ml) was collected from fifty newly diag-
nosed ovarian cancer patients who had histopathologically
confirmed epithelial ovarian cancer. The study group was
subjected to a structured questionnaire (regarding demo-
graphic, medical, lifestyle and reproductive information).
Fifty controls were matched with respect to age, meno-
pausal status and month of blood draw. The study was ap-
proved by the institutional ethics committee of Maulana
Azad Medical College, New Delhi.
Serum vitamin D estimation
The serum vitamin D was measured by electrochemi-
luminescence immunoassay method using Elecsys Total
Vitamin D (25-OH) kit (Roche diagnostics, Mannheim,
Germany) adapted to ELECSYS 2010 (Roche diagnostics,
Mannheim, Germany).
Genotype analysis
Genotyping was performed without the knowledge of the
case/control status of the study subjects. Genomic DNA
was extracted from blood samples collected in EDTA vials
using DNA sure blood mini kit (Nucleo-pore, Genetix
Biotech Asia Pvt. Ltd., New Delhi, India) according to the
manufacturer’s instructions. VDR FokI genotype was ana-
lyzed using PCR- RFLP. The DNA was amplified by poly-
merase chain reaction using primers described by Harris
et al. [14]. The primers used for PCR–RFLP were Forward
5′- AGCTGGCCCTGGCACTGACTCTGCTCT -3′ and
Reverse 5′- ATGGAAACACCTTGCTTCTTCTCCCTC -3′ resulting in a PCR product of 265 bp. The amplification
was accomplished with a 50 μl reaction mixture contain-
ing 5 μl of 20 ng template DNA, 0.25 μl 25 pmol of each
primer, 2.5 μl 10 mM dNTPs, 1.5 μl of 20 mM MgCl2,
0.3 μl of 5 U/ μl Taq polymerase with 2.5 μl of 10X Taq
Buffer (Fermentas, MA, USA). PCR conditions were as
follows: Initial denaturation at 94°C for 10 minutes
followed by 35 cycles of denaturation at 94°C for 45 sec-
onds, annealing at 60°C for 45 seconds, extension at 72°C
for 45 seconds and final extension at 72°C for 5 minutes.
The amplicons were digested with 4 units of FokI enzyme
(NEB, MA, USA) by incubating at 37°C for 4 hours. The
presence of T allele created a restriction site in the ampli-
fied region which was cut by FokI to produce 2 fragments
of 69 bp and 196 bp visualized on 3.5% agarose gel
containing ethidium bromide (Figure 1).
Statistical analysis
Statistical analysis was done with SPSS version 17.0 (SPSS,
Inc., Chicago IL). Independent T test (for parametric data)
and Mann Whitney U test (for nonparametric data) were
Figure 2 Box plot showing the distribution of vitamin D levels in ovarian cancer cases and controls.
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min D and ovarian cancer was determined using logistic
regression. The associations between CT and TT geno-
types and risk of ovarian cancer were estimated by com-
puting the odds ratios (ORs) and their 95% confidence
intervals (CIs). Synergy factor was calculated to measure
the interaction between vitamin D deficiency and VDR
polymorphism (FokI) [15]. Statistical difference was con-
sidered significant for p values <0.05.
Results
General characteristics of study population
The age, parity, menopausal status, family history of
relevant cancers and method of contraception among
cases and healthy controls are summarized in Table 1.
Ovarian cancer patients were between the age group
20–80 years with the mean age being 47 years. There
were three patients in stage I ovarian cancer, four pa-
tients in stage II, forty in stage III and three patients in
stage IV. Six patients had grade I (well-differentiated)
tumour, twenty nine had grade II (moderately differenti-
ated) tumour and fifteen had grade III (poorly- differen-
tiated) tumour.
Serum vitamin D levels
The median of serum vitamin D levels in cases were
20.1 ng/ml which was significantly (p value <0.03) lower
than that in controls (24.6 ng/ml) (Figure 2). Women
with low vitamin D levels (bottom 33%) were at a higher
risk for epithelial ovarian cancer (OR:3.0; CI: 1.01-7.40;
p value < 0.05) than those with high levels (top 33%)
(Table 2). Serum vitamin D levels in ovarian cancer pa-
tients who were in the reproductive age group were notTable 2 Odds ratio (OR) and 95% CI for ovarian cancer
according to tertile levels of baseline vitamin D levels
Median (Range) of serum
vitamin D levels in ng/ml
Ovarian cancer
patients
Controls OR (95% CI)
Unadjusted
p value*
Top tertile 36 (27–47) 17 22 1
Bottom tertile 11.9 (5–16.2) 16 10 3.0 (1.01-7.40) < 0.05
* by logistic regression.significantly different from that of control subjects in the
same age group. But the levels were significantly differ-
ent between cases and controls in post-menopausal
group (Table 3). There was no significant difference with
respect to other parameters like clinical staging and
histological grading (Table 4).
Genotype distribution
The genotyping results are shown in Table 5. In the case
group, 26 patients had FF genotype, 19 had Ff genotype
(heterozygous) and 5 patients had the mutant ff geno-
type. In the control group, 36 had FF genotype, 10 had
Ff genotype and 4 had ff genotype. Distribution of VDR
genotype was significantly different (χ2 = 4.24, p value <
0.05) in ovarian cancer patients from that in controls.
By unconditional logistic regression analysis, it was
found that in comparison to the CC genotype, the CT and
TT genotype (combined) were at significantly higher risk
of ovarian cancer (OR = 2.37, 95% CI 1.04-5.44, p < 0.05).
To measure the combined effect of vitamin D defi-
ciency (vitamin D <20 ng/ml) and FokI polymorphism,
we calculated their synergy factor which was not found
to be statistically significant (Table 6).
Discussion
Vitamin D was known to be involved in bone metabol-
ism but its role in other diseases like cancer, auto-
immune diseases and diabetes mellitus is being studied
extensively only in recent times. Ovarian cancer, on the
other hand is a disease whose etiology is attributed to in-
cessant ovulation and hormonal imbalance. Potential
role of vitamin D in cancer prevention has been widelyTable 3 Median (range) of serum vitamin D (in ng/ml) in
reproductive and post-menopausal age group in ovarian
cancer patients and controls
Ovarian cancer patients Controls p value*
Reproductive
age group
18.3 (7.2-61.8)(n = 19) 21.4 (7.3-40)(n = 20) 0.41
Post-menopausal
women
20.6 (6.93-43)(n = 30) 27.8 (7.7-47)(n = 31) 0.03
* by Mann Whitney U test.
Table 4 Comparison of vitamin D levels in different
clinical stages and histological grading in ovarian cancer
Median (Range) of
vitamin D in ng/ml
p value*
Clinical staging
Stage I and II (n = 7) 18.7 (12.8,30.5) 0.855
Stage III (n = 40) 20.8 (6.9,61.8)
Stage IV (n = 3) 14 (12.9,26)
Histological grading
Well-differentiated (n = 6) 16.7 (11,24.7) 0.442
Moderately differentiated (n = 29) 20.6 (6.9,61.8)
Poorly-differentiated (n = 15) 17 (7.2,37)
* by Kruskal wallis test.
Table 6 Synergy factor (SF) in ovarian cancer between









OR SF (p value)
- - 25 15 Reference 2.1 (0.4)
+ - 10 10 1.67
+ + 4 14 5.83
- + 11 11 1.66














Caucasian 71/144 FF 1 Reference 0.04
Japanese 93/172 Ff 2.5 1.3-4.8
ff 2.1 0.8-5.2
FF 1 Reference 0.87
Ff 1.2 0.7-2.0
Mohapatra et al. Journal of Ovarian Research 2013, 6:37 Page 4 of 6
http://www.ovarianresearch.com/content/6/1/37described [16-18]. There exist numerous studies which
show inverse relationship of cancers of different organs
with sun exposure including ovarian cancer [19-21].
However only a few studies have evaluated the role of
serum vitamin D levels in ovarian cancer, and most are
on Caucasian population [5,6]. To our knowledge this is
the first study showing a clear relationship between vita-
min D deficiency, VDR functional polymorphism (FokI)
and risk of ovarian cancer in Indian population.
It may seem surprising to see the prevalence of vitamin D
deficiency in a tropical country like India. The reason behind
this could be the lifestyle of people where most of the
women stay indoors. The poor intake of dairy products due
to social factor and dietary habits may also contribute to
this. A few studies conducted on general prevalence of vita-
min D deficiency in India show alarming trends [22,23]. In
our study, the participants in the highest tertile had a signifi-
cant lower risk of ovarian cancer than those in the lowest
tertile. On subset analysis, the mean vitamin D level of ovar-
ian cancer (21 ± 9.1 ng/ml) was significantly lower than that
of controls (26.5 ± 8.5 ng/ml) in the post-menopausal group.
The reason could be that in post-menopausal state there is
an increased need of vitamin D due to decreased expression
of VDR caused by decrease in estrogen levels [24].
In the present study, we have observed that VDR gene
polymorphism (Fok1) is associated with the risk of devel-
oping ovarian cancer. FokI (rs2228750) is a coding
nonsynonymous single nucleotide polymorphism (SNP)
in the translation initiation code that has been reported
to have functional significance in several in vitro studies






p value Odds ratio
(95% CI)
p value*
CC(FF) 26 (52%) 36 (72%) 4.24(1) <0.05 1
CT + TT
(Ff + ff)
24 (48%) 14 (28%) 2.37 (1.04-5.44) <0.05
*by logistic regression.independent risk marker as it has not been reported to be in
linkage disequlibrium with other VDR polymorphisms [26].
In HELA cells, transcriptional activation studies using a re-
porter construct under the control of a short portion of the
rat 24-hydroxylase gene promoter region (−291- + 9)
containing a vitamin D responsive element (VDRE) have
shown that the short 424 amino acid VDR protein variant
to be more active than the long 427 amino acid variant [27].
In a study with MCF-7 breast cancer cell line, it was seen
that VDR-ff and VDR-FF expressing cells were morpho-
logically similar, but the VDR-FF variant is more efficient in
mediating 1,25 (OH)2 D3 action. The reason for increased
vitamin D efficacy in VDR-FF was probably due to increased
VDR protein stability. VDR-FF cells were resistant to the ef-
fects of the protein synthesis inhibitor cycloheximide even
without 1, 25(OH)2 D3 treatment, indicating that the VDR-
FF protein may be more stable than VDR-ff protein [28]. In
conclusion, both protein stability and higher activity of the
VDR-FF variant contribute to this variant’s enhanced re-
sponse to vitamin D. Our results show that the CT and TT
genotype were associated with a twofold increase in ovarian
cancer risk. Other studies that have explored the relation-
ship between VDR gene polymorphism (FokI) and risk for
ovarian cancer are summarized in Table 7.ff 0.9 0.4-2.2
Clendenen et al.
2008 [11]





U.S 1473/2006 1.16 1.00-1.35 0.03
Lurie et al.
2010 [13]
U.S 1820/3479 1.14 1.01-1.28 0.03
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min D deficiency and vitamin D receptor polymorphism
is expected to be due to modulation of same target mol-
ecules. But we observed that low serum vitamin D levels
along with homozygous TT allele didn’t lead to synergis-
tic increase in the risk of epithelial ovarian cancer (syn-
ergy factor:2; p value < 0.4). There are other novel
ligands of vitamin D receptor and co-modulators influ-
encing vitamin D signaling mechanism [29-31]. The
non-synergistic effect indicates that these novel ligands
of vitamin D receptor and co-modulators might also
play a role in determining the risk of ovarian cancer
which is worth exploring.
Conclusion
It is suggested that low vitamin D levels might be a risk
factor for ovarian cancer. Additionally, VDR gene (FokI)
polymorphism may be a genetic modifier for ovarian
cancer risk in Indian population. The homozygous FokI
(TT) and heterozygous (CT) polymorphism and vitamin
D levels have independent effect on cancer development
and are not synergistic in their actions. However, inde-
pendent large population-based prospective studies are
needed to validate our findings and to facilitate rigorous
analyses of subgroups. Thus our study provides evidence
that the protective effect of vitamin D supplementation
against ovarian cancer (especially in postmenopausal
women) is worth investigating in Indian population.
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